Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Enliven Therapeutics's ROE % for the quarter that ended in Jun. 2026 was -19.27%. Enliven Therapeutics's PB Ratio for the quarter that ended in Jun. 2026 was 4.15.
Enliven Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Jun. 2026 was -4.64%.
Enliven Therapeutics ROE % Adjusted to Book Value Related Terms
Enliven Therapeutics ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for Enliven Therapeutics's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enliven Therapeutics ROE % Adjusted to Book Value Chart
ELVN vs PBLS, CPRX, DNLI: ROE % Adjusted to Book Value Comparison
For the Biotechnology subindustry, Enliven Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enliven Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Enliven Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Enliven Therapeutics's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of -4.64% mean?
Enliven Therapeutics (ELVN) has a ROE % Adjusted to Book Value of -4.64% as of Jun. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Enliven Therapeutics and its competitors.
Is Enliven Therapeutics' ROE % Adjusted to Book Value too high?
Enliven Therapeutics' current ROE % Adjusted to Book Value is -4.64%. Overall, Enliven Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Enliven Therapeutics' ROE % Adjusted to Book Value compare to PBLS and CPRX?
Enliven Therapeutics' ROE % Adjusted to Book Value of -4.64% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Enliven Therapeutics and its competitors. Enliven Therapeutics's current ROE % Adjusted to Book Value is -4.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enliven Therapeutics stock overvalued right now?
Enliven Therapeutics (ELVN) has a current ROE % Adjusted to Book Value of -4.64%. The current ROE % Adjusted to Book Value is -4.64%. Enliven Therapeutics' overall GF Score™ is 31/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Enliven Therapeutics (ELVN), the current ROE % Adjusted to Book Value is -4.64% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
31GF Score
Get the complete analysis for ELVN
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ELVN has been successfully added to your 
